- Home
- NBY vs BLRX Comparison
NBY vs BLRX Comparison
Compare NBY & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- BLRX
- Stock Information
- Founded
- NBY 2000
- BLRX 2003
- Country
- NBY United States
- BLRX Israel
- Employees
- NBY N/A
- BLRX N/A
- Industry
- NBY
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- BLRX Health Care
- Exchange
- NBY Nasdaq
- BLRX Nasdaq
- Market Cap
- NBY 15.7M
- BLRX 17.0M
- IPO Year
- NBY 2007
- BLRX 2011
- Fundamental
- Price
- NBY $2.60
- BLRX $4.04
- Analyst Decision
- NBY Strong Buy
- BLRX Strong Buy
- Analyst Count
- NBY 1
- BLRX 2
- Target Price
- NBY $0.85
- BLRX $19.00
- AVG Volume (30 Days)
- NBY 21.3M
- BLRX 33.6K
- Earning Date
- NBY 11-06-2025
- BLRX 08-14-2025
- Dividend Yield
- NBY N/A
- BLRX N/A
- EPS Growth
- NBY N/A
- BLRX N/A
- EPS
- NBY 0.41
- BLRX N/A
- Revenue
- NBY $9,781,000.00
- BLRX $17,251,000.00
- Revenue This Year
- NBY $23.91
- BLRX N/A
- Revenue Next Year
- NBY $32.05
- BLRX N/A
- P/E Ratio
- NBY $6.50
- BLRX N/A
- Revenue Growth
- NBY 113.47
- BLRX 1.19
- 52 Week Low
- NBY $0.46
- BLRX $2.30
- 52 Week High
- NBY $4.44
- BLRX $26.80
- Technical
- Relative Strength Index (RSI)
- NBY 58.86
- BLRX 55.55
- Support Level
- NBY $2.28
- BLRX $3.42
- Resistance Level
- NBY $3.12
- BLRX $4.36
- Average True Range (ATR)
- NBY 0.57
- BLRX 0.26
- MACD
- NBY 0.04
- BLRX 0.07
- Stochastic Oscillator
- NBY 48.32
- BLRX 65.96
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.